Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Emerging SARS-CoV-2 Variants: Genetic Variability and Clinical Implications
Aakriti Dubey, Shweta Choudhary, Pravindra Kumar, et al.
Current Microbiology (2021) Vol. 79, Iss. 1
Open Access | Times Cited: 71

Showing 1-25 of 71 citing articles:

Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant
Fanglei Zuo, Hassan Abolhassani, Likun Du, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 137
Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?
Manish Dhawan, AbdulRahman A. Saied, Saikat Mitra, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 154, pp. 113522-113522
Open Access | Times Cited: 93
Evolution and implications of SARS-CoV-2 variants in the post-pandemic era
Emery Manirambona, Olalekan John Okesanya, Noah Olabode Olaleke, et al.
Deleted Journal (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 8
Individual genetic variability mainly of Proinflammatory cytokines, cytokine receptors, and toll‐like receptors dictates pathophysiology of COVID‐19 disease
Mohammad Kazem Vakil, Yaser Mansoori, Ghaidaa Raheem Lateef Al‐Awsi, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 9, pp. 4088-4096
Open Access | Times Cited: 30
In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1
Andrei A. Pochtovyi, Daria D. Kustova, Andrei E. Siniavin, et al.
Vaccines (2023) Vol. 11, Iss. 10, pp. 1533-1533
Open Access | Times Cited: 20
Transformative Approaches in SARS-CoV-2 Management: Vaccines, Therapeutics and Future Direction
Ankita Saha, Shweta Choudhary, Priyanshu Walia, et al.
Virology (2025) Vol. 604, pp. 110394-110394
Closed Access
Decoding Omicron: Genetic Insight into Its Transmission Dynamics, Severity Spectrum and Ever-Evolving Strategies of Immune Escape in comparison with other SARS-CoV-2 variants.
Kundan Tandel, Divya Niveditha, Sanjay Singh, et al.
Diagnostic Microbiology and Infectious Disease (2025) Vol. 111, Iss. 3, pp. 116705-116705
Closed Access
Investigation of Immunoreactivity Profiles and Epitope Landscape in Divergent COVID-19 Trajectories and SARS-CoV-2 Variants
Surbhi Bihani, Arka Ray, Dhanush Borishetty, et al.
Journal of Proteome Research (2025)
Closed Access
In‐Silico Screening, Molecular Dynamics, and DFT Analysis of ZINC and ChEMBL Library Compounds for SARS‐CoV‐2 Main Protease Inhibition
Shailendra Verma, Amit Dubey, Rashika Singh, et al.
ChemistrySelect (2025) Vol. 10, Iss. 4
Closed Access
Peptides Corresponding to the Receptor‐Binding Domain (RBD) of Several SARS‐CoV‐2 Variants Of Concern Prevent Recognition of the Human ACE2 Receptor and Consecutive Cell Infections
Mandy Schwarze, Alexandra Brakel, Ralf Hoffmann, et al.
ChemMedChem (2025)
Open Access
SARS-CoV-2 and COVID-19: A Narrative Review
Andrew D. Blann, Rebekka Heitmar
British Journal of Biomedical Science (2022) Vol. 79
Open Access | Times Cited: 26
Interim analysis from a phase 2 randomized trial of EuCorVac-19: a recombinant protein SARS-CoV-2 RBD nanoliposome vaccine
Jonathan F. Lovell, Yeong Ok Baik, Seuk Keun Choi, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 25
SARS-CoV-2 Spike Proteins and Cell–Cell Communication Induce P-Selectin and Markers of Endothelial Injury, NETosis, and Inflammation in Human Lung Microvascular Endothelial Cells and Neutrophils: Implications for the Pathogenesis of COVID-19 Coagulopathy
Biju Bhargavan, Georgette D. Kanmogne
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 16, pp. 12585-12585
Open Access | Times Cited: 15
Molecular Epidemiology and Diversity of SARS-CoV-2 in Ethiopia, 2020–2022
Abay Sisay, Derek Tshiabuila, Stephanie van Wyk, et al.
Genes (2023) Vol. 14, Iss. 3, pp. 705-705
Open Access | Times Cited: 14
SARS-CoV-2 Omicron: Viral Evolution, Immune Evasion, and Alternative Durable Therapeutic Strategies
Hailong Guo, Sha Ha, Jason Botten, et al.
Viruses (2024) Vol. 16, Iss. 5, pp. 697-697
Open Access | Times Cited: 4
Review of concerned SARS-CoV-2 variants like Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529), as well as novel methods for reducing and inactivating SARS-CoV-2 mutants in wastewater treatment facilities
Sasan Zahmatkesh, Mika Sillanpää, Yousof Rezakhani, et al.
Journal of Hazardous Materials Advances (2022) Vol. 7, pp. 100140-100140
Open Access | Times Cited: 21
Can the SARS-CoV-2 Omicron Variant Confer Natural Immunity against COVID-19?
Abdul Hawil Abas, Siti Marfuah, Rinaldi Idroes, et al.
Molecules (2022) Vol. 27, Iss. 7, pp. 2221-2221
Open Access | Times Cited: 19
Some common deleterious mutations are shared in SARS-CoV-2 genomes from deceased COVID-19 patients across continents
Md. Aminul Islam, Abdullah Al Marzan, Md Sakil Arman, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 11
Cohort profile:Stop the Spread Ottawa (SSO)—a community-based prospective cohort study on antibody responses, antibody neutralisation efficiency and cellular immunity to SARS-CoV-2 infection and vaccination
Erin Collins, Yannick Galipeau, Corey Arnold, et al.
BMJ Open (2022) Vol. 12, Iss. 9, pp. e062187-e062187
Open Access | Times Cited: 15
Dynamics of Viral Infection and Evolution of SARS-CoV-2 Variants in the Calabria Area of Southern Italy
Carmela De Marco, Claudia Veneziano, Alice Massacci, et al.
Frontiers in Microbiology (2022) Vol. 13
Open Access | Times Cited: 14
Unravelling Insights into the Evolution and Management of SARS-CoV-2
Aganze Gloire-Aimé Mushebenge, Samuel Chima Ugbaja, Nonkululeko Avril Mbatha, et al.
BioMedInformatics (2024) Vol. 4, Iss. 1, pp. 385-409
Open Access | Times Cited: 2
Structure-guided mutations in CDRs for enhancing the affinity of neutralizing SARS-CoV-2 nanobody
Vishakha Singh, Mandar Bhutkar, Shweta Choudhary, et al.
Biochemical and Biophysical Research Communications (2024) Vol. 734, pp. 150746-150746
Closed Access | Times Cited: 2
SARS-CoV-2 Spike Proteins and Cell–Cell Communication Inhibits TFPI and Induces Thrombogenic Factors in Human Lung Microvascular Endothelial Cells and Neutrophils: Implications for COVID-19 Coagulopathy Pathogenesis
Biju Bhargavan, Georgette D. Kanmogne
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 18, pp. 10436-10436
Open Access | Times Cited: 12
Unraveling antiviral efficacy of multifunctional immunomodulatory triterpenoids against SARS‐COV‐2 targeting main protease and papain‐like protease
Shweta Choudhary, Sanketkumar Nehul, Ankur Singh, et al.
IUBMB Life (2023) Vol. 76, Iss. 5, pp. 228-241
Open Access | Times Cited: 7
Effectiveness of mRNA COVID-19 Vaccination on SARS-CoV-2 Infection and COVID-19 in Sicily over an Eight-Month Period
Emanuele Amodio, Giuseppe Vella, Vincenzo Restivo, et al.
Vaccines (2022) Vol. 10, Iss. 3, pp. 426-426
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top